Enhancing the dissolution of phenylbutazone using Syloid® based mesoporous silicas for oral equine applications [PDF]
Three mesoporous silica excipients (Syloid® silicas AL-1 FP, XDP 3050 and XDP 3150) were formulated with a model drug known for its poor aqueous solubility, namely phenylbutazone, in an attempt to enhance the extent and rate of drug dissolution. Although
Laura J. Waters+7 more
doaj +5 more sources
Background Gastrointestinal (GI) injury and dysbiosis are adverse events associated with nonsteroidal anti‐inflammatory drug (NSAID) use in horses. Phenylbutazone has been shown to alter GI barrier function both in vitro and ex vivo, but its effects on ...
Canaan M. Whitfield‐Cargile+8 more
doaj +2 more sources
Joint Statement of EFSA and EMA on the presence of residues of phenylbutazone in horse meat [PDF]
Controls in Member States have revealed the presence of phenylbutazone in horse carcasses intended for the food chain. Following the request from the European Commission, the European Medicines Agency and the European Food Safety Authority jointly ...
European Food Safety Authority
doaj +3 more sources
Toward of Safer Phenylbutazone Derivatives by Exploration of Toxicity Mechanism
A drug design for safer phenylbutazone was been explored by reactivity and docking studies involving single electron transfer mechanism, as well as toxicological predictions.
Rosivaldo S. Borges+10 more
doaj +2 more sources
Effect of Phenylbutazone Administration on Insulin Sensitivity in Horses With Insulin Dysregulation [PDF]
Background Phenylbutazone is prescribed to manage pain caused by hyperinsulinemia‐associated laminitis. Phenylbutazone reduces glucose and insulin concentrations in horses with insulin dysregulation (ID) but the underlying mechanism of action is unknown.
Kate L. Kemp+3 more
doaj +2 more sources
Effect of phenylbutazone on insulin secretion in horses with insulin dysregulation
Background Phenylbutazone is often prescribed to manage pain caused by hyperinsulinemia‐associated laminitis, but in diabetic people nonsteroidal anti‐inflammatory drugs increase insulin secretion and pancreatic activity.
Kate L. Kemp+2 more
doaj +2 more sources
Right dorsal colitis in horses: A multicenter retrospective study of 35 cases [PDF]
Background Right dorsal colitis (RDC) is a nonsteroidal anti‐inflammatory drug (NSAID) induced, protein losing enteropathy in horses associated with a high case fatality rate.
Jordan Flood+8 more
doaj +2 more sources
Effects of phenylbutazone, firocoxib, and dipyrone on the diuretic response to furosemide in horses [PDF]
Background Treatment with phenylbutazone (nonselective COX inhibitor) decreases the diuretic and natriuretic effects of furosemide by nearly 30% but the effects of COX‐2 specific inhibitors (firocoxib) and atypical NSAIDs (dipyrone) are unknown ...
Julianne M. White+2 more
doaj +2 more sources
Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation [PDF]
Background Phenylbutazone is prescribed for laminitis‐associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID).
Kate L. Kemp+2 more
doaj +2 more sources
Phenylbutazone concentrations in synovial fluid following administration via intravenous regional limb perfusion in the forelimbs of six adult horses [PDF]
BackgroundPain management is critical to equine welfare with non-steroidal anti-inflammatory drugs (NSAID) commonly used in horses. However, systemic NSAID use is limited by harmful gastrointestinal and renal side effects.
Molly O’Brien+7 more
doaj +2 more sources